HUE048395T2 - Pirrolo[2,3-C]piridinek mint képalkotó szerek neurofibrilláris fonatok számára - Google Patents

Pirrolo[2,3-C]piridinek mint képalkotó szerek neurofibrilláris fonatok számára

Info

Publication number
HUE048395T2
HUE048395T2 HUE15806980A HUE15806980A HUE048395T2 HU E048395 T2 HUE048395 T2 HU E048395T2 HU E15806980 A HUE15806980 A HU E15806980A HU E15806980 A HUE15806980 A HU E15806980A HU E048395 T2 HUE048395 T2 HU E048395T2
Authority
HU
Hungary
Prior art keywords
neurofibrillar
braids
pyridines
pyrrolo
imaging agents
Prior art date
Application number
HUE15806980A
Other languages
English (en)
Hungarian (hu)
Inventor
Abbas Walji
Eric Hostetler
Thomas Greshock
Jing Li
Keith Moore
Idriss Bennacef
James Mulhearn
Harold Selnick
Yaode Wang
Kun Yang
Jianmin Fu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of HUE048395T2 publication Critical patent/HUE048395T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
HUE15806980A 2014-06-13 2015-06-09 Pirrolo[2,3-C]piridinek mint képalkotó szerek neurofibrilláris fonatok számára HUE048395T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2014/079834 WO2015188368A1 (en) 2014-06-13 2014-06-13 Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles

Publications (1)

Publication Number Publication Date
HUE048395T2 true HUE048395T2 (hu) 2020-08-28

Family

ID=54832744

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15806980A HUE048395T2 (hu) 2014-06-13 2015-06-09 Pirrolo[2,3-C]piridinek mint képalkotó szerek neurofibrilláris fonatok számára

Country Status (15)

Country Link
US (2) US9808542B2 (enExample)
EP (1) EP3154970B1 (enExample)
JP (1) JP6513107B2 (enExample)
KR (1) KR102478430B1 (enExample)
CN (1) CN106661018B (enExample)
AU (1) AU2015274843B2 (enExample)
BR (1) BR112016028345B1 (enExample)
CA (1) CA2948528C (enExample)
DK (1) DK3154970T3 (enExample)
ES (1) ES2763095T3 (enExample)
HU (1) HUE048395T2 (enExample)
MX (1) MX375282B (enExample)
PL (1) PL3154970T3 (enExample)
RU (1) RU2695373C2 (enExample)
WO (2) WO2015188368A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5422782B1 (ja) 2012-12-21 2014-02-19 独立行政法人放射線医学総合研究所 脳内に蓄積したタウタンパク質をイメージングするための新規化合物
WO2018015549A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
EP3487545A1 (en) * 2016-07-22 2019-05-29 AC Immune S.A. Compounds for imaging tau protein aggregates
US11541033B2 (en) 2017-06-02 2023-01-03 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating Alzheimer's disease
RU2728717C1 (ru) 2017-06-02 2020-07-30 ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. Средство для профилактики или лечения спиноцеребеллярной атаксии
CN110691594A (zh) * 2017-06-02 2020-01-14 富士胶片富山化学株式会社 Tau蛋白病预防或治疗剂
JP7282028B2 (ja) 2017-06-02 2023-05-26 富士フイルム富山化学株式会社 脳萎縮予防または治療剤
KR20200003102A (ko) 2017-06-02 2020-01-08 후지필름 도야마 케미컬 가부시키가이샤 아밀로이드 β 단백질량 감소제
JP7227914B2 (ja) 2017-10-30 2023-02-22 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用
EP3743426A1 (en) 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates
WO2019145291A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Gamma-carboline compounds for the detection of tau aggregates
CN111770924B (zh) * 2018-04-04 2023-05-09 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂
KR102017324B1 (ko) * 2018-04-30 2019-09-02 경북대학교 산학협력단 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도
CN112384517B (zh) * 2018-05-09 2023-07-14 新旭生技股份有限公司 杂芳基化合物及其用途
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス, インコーポレイテッド Sarm1阻害剤
CN108676007B (zh) * 2018-06-22 2020-06-26 厦门大学 放射性核素标记的苯并蝶啶类衍生物及其制备方法和应用
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
CA3161455A1 (en) 2019-11-13 2021-05-20 Aprinoia Therapeutics Limited Compounds for degrading tau protein aggregates and uses thereof
US20220008563A1 (en) * 2020-07-10 2022-01-13 The Regents Of The University Of California Radiolabelled and nonradiolabelled pegylated compounds and uses thereof
BR112023002139A2 (pt) * 2020-08-06 2023-04-18 Chdi Foundation Inc Compostos de heterobiarila e agentes de imageamento para proteína huntingtina
CN112939753B (zh) * 2020-09-15 2022-04-05 浙江大学 一种1-茚酮类化合物的合成方法
KR102240400B1 (ko) * 2020-11-19 2021-04-15 한국원자력연구원 베타-아밀로이드 검출용 수용성 화합물
CN112745299B (zh) * 2021-01-07 2022-01-25 温州大学 4-氰基-7,8-二氢异喹啉衍生物及其制备方法和应用
TWI782769B (zh) * 2021-10-28 2022-11-01 行政院原子能委員會核能研究所 一種新穎神經纖維糾結微管相關蛋白質Tau造影化合物、其製備方法及用途
CN114149425A (zh) * 2021-11-16 2022-03-08 上海应用技术大学 5-氟甲基吡啶衍生物和18-f同位素标记的5-氟甲基吡啶衍生物及其制备与应用
CN114276259B (zh) * 2022-01-04 2022-12-06 济川(上海)医学科技有限公司 一种马来酸二甲茚定关键中间体的制备方法
CN115417816B (zh) * 2022-09-05 2024-01-26 江苏南大光电材料股份有限公司 一种3,6-二溴-1-氯-异喹啉的制备方法
WO2025230262A1 (ko) * 2024-04-29 2025-11-06 심플렉스 주식회사 신규한 헤테로아릴 유도체 및 이의 aak1 억제 용도
WO2026153567A1 (zh) * 2025-01-20 2026-07-23 天津恒瑞医药有限公司 一种吡咯并[2,3-c]吡啶类衍生物及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451566A (en) 1993-11-17 1995-09-19 Zeneca Limited Herbicidal pyrrolopyridine compounds
AU2005336513B2 (en) * 2004-10-07 2012-08-09 Merck Sharp & Dohme Llc Thiazolyl mGluR5 antagonists and methods for their use
US20080027044A1 (en) * 2006-06-13 2008-01-31 Kim Lewis Prodrug antibiotic screens
WO2008103615A1 (en) 2007-02-21 2008-08-28 Kalypsys, Inc. Isoquinolines useful as inducible nitric oxide synthase inhibitors
TW200902499A (en) * 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
EP2296474A1 (en) * 2008-05-30 2011-03-23 Merck Sharp & Dohme Corp. Novel substituted indoles
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン, エルエルシー 複素環式化合物およびその使用
GB201004311D0 (en) * 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
US8684313B2 (en) 2011-02-02 2014-04-01 Ocean Rodeo Sports Inc. Inflatable kite with leading edge swept forwards at wingtip
US20140348748A1 (en) * 2011-09-16 2014-11-27 Lisheng Cai Beta-amyloid imaging agents, methods of manufacture, and methods of use thereof
US20150336948A1 (en) * 2012-05-29 2015-11-26 Merck Sharp & Dohme Corp. Isotopically Labeled Biaryl Urea Compounds
CN103450152B (zh) * 2012-06-04 2015-11-18 济南海乐医药技术开发有限公司 基于吲唑、吲哚或氮杂吲唑、氮杂吲哚的双芳基脲类结构抗肿瘤药物
GB201304526D0 (en) * 2013-03-13 2013-04-24 Proximagen Ltd New compounds
GB201404498D0 (en) * 2014-03-13 2014-04-30 Proximagen Ltd New compounds

Also Published As

Publication number Publication date
MX375282B (es) 2025-03-06
RU2016150404A3 (enExample) 2018-11-30
KR102478430B1 (ko) 2022-12-15
EP3154970A4 (en) 2017-11-15
RU2019115483A (ru) 2019-06-13
KR20170016481A (ko) 2017-02-13
AU2015274843B2 (en) 2018-11-22
PL3154970T3 (pl) 2020-04-30
CA2948528A1 (en) 2015-12-17
CA2948528C (en) 2022-05-31
ES2763095T3 (es) 2020-05-27
US9808542B2 (en) 2017-11-07
WO2015188368A1 (en) 2015-12-17
WO2015191506A3 (en) 2016-02-04
US20180071412A1 (en) 2018-03-15
RU2016150404A (ru) 2018-07-18
BR112016028345B1 (pt) 2022-11-29
CN106661018A (zh) 2017-05-10
AU2015274843A1 (en) 2016-11-10
RU2695373C2 (ru) 2019-07-23
MX2016016384A (es) 2017-05-01
JP2017521387A (ja) 2017-08-03
BR112016028345A2 (pt) 2017-08-22
US10022461B2 (en) 2018-07-17
JP6513107B2 (ja) 2019-05-15
US20170119912A1 (en) 2017-05-04
DK3154970T3 (da) 2020-01-20
WO2015191506A2 (en) 2015-12-17
BR112016028345A8 (pt) 2021-06-29
EP3154970A2 (en) 2017-04-19
EP3154970B1 (en) 2019-11-06
CN106661018B (zh) 2019-07-19

Similar Documents

Publication Publication Date Title
DK3154970T3 (da) Pyrrolo[2,3-c]pyridiner som billeddannelsesmidler til neurofibrillære sammenfiltringer
DK3355884T3 (da) Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
HUE049175T2 (hu) Eljárás anti-CD79b immunkonjugátumok alkalmazására
IL252053A0 (en) Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
DK3351071T3 (da) Strømskinneanordning
DK3286188T3 (da) Isoxazolyl-substituerede imidazopyridiner
ZA201701461B (en) Antibody formulations
HUE048576T2 (hu) 1H-pirazolo[4,3B]piridinek, mint PDE1 inhibitorok
DK3325487T3 (da) Formulering til bløde, anticholinerge analoger
ITUB20153347A1 (it) Apparato per la videocomunicazione
HUE045024T2 (hu) Poliamid készítmények
HUE054245T2 (hu) Immunszupresszáns formuláció
IL251859A0 (en) Methotrexate formulation
DK3277690T3 (da) Spirocykliske forbindelser
DK3194389T3 (da) Ssao inhibitorer afledt af imidazo[4,5-c]pyridin
ZA201900113B (en) Ethynyl derivatives
BR112016027580A2 (pt) Formulação de ceritinib
DK2904938T3 (da) Modulær platform
DK2910786T3 (da) Roterbart apparat
GB2568406B (en) Play apparatus
ITUB20153121A1 (it) Apparato per l'ozonoterapia
AU5624P (en) Triumph Fragaria xananassa
HUP1400561A2 (hu) Mozgó alkatrész nélküli lézeres jármû osztályozó
ES1105055Y (es) Pista de juego
DK3303316T3 (da) Ethynylderivater